David C. Oxley
Direktor/Vorstandsmitglied bei TB Biosciences, Inc.
Profil
David C.
Oxley is currently a Non-Executive Director at TB Biosciences, Inc. He previously held the position of Executive VP-Worldwide Sales & Marketing at Trinity Biotech Plc and Vice President-Emerging Market Sales at Plus Therapeutics, Inc. He will also serve as the President-International at Exopharm Ltd.
from 2021 to 2023.
Aktive Positionen von David C. Oxley
| Unternehmen | Position | Beginn |
|---|---|---|
TB Biosciences, Inc.
 TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA. | Direktor/Vorstandsmitglied | 01.08.2013 |
Ehemalige bekannte Positionen von David C. Oxley
| Unternehmen | Position | Ende |
|---|---|---|
| EXOPHARM | Präsident | 01.01.2023 |
| TRINITY BIOTECH PLC | Vertrieb & Marketing | - |
| PLUS THERAPEUTICS, INC. | Vertrieb & Marketing | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PLUS THERAPEUTICS, INC. | Health Technology |
| TRINITY BIOTECH PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
TB Biosciences, Inc.
TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA. | Health Services |
Exopharm Ltd.
 Exopharm Ltd. Pharmaceuticals: MajorHealth Technology Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia. | Health Technology |